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During human immunodeficiency virus type 1 (HIV-1) virion assembly, cleavage of the Gag precursor by the
viral protease results in the transient appearance of a nucleocapsid-p1-p6 intermediate product designated
p15NC. Utilizing the p15NC precursor protein produced with an in vitro transcription-translation system or
purified after expression in Escherichia coli, we have demonstrated that RNA is required for efficient cleavage
of HIV p15NC. Gel mobility shift and nitrocellulose filter binding experiments indicate that purified p15NC
protein specifically binds its corresponding mRNA with an estimated Kd of 1.5 nM. Binding was not affected
by the presence or absence of zinc or EDTA. Moreover, mutagenesis of the cysteine residues within either of
the two Cys-His arrays had no effect on RNA binding or on RNA-dependent cleavage by the viral protease. In
contrast, decreased binding of RNA and diminished susceptibility to cleavage in vitro were observed with
p15NC-containing mutations in one or more residues within the triplet of basic amino acids present in the
region between the two zinc fingers. In addition, we found that 21- to 24-base DNA and RNA oligonucleotides
of a particular sequence and secondary structure could substitute for p15 RNA in the enhancement of p15NC
cleavage. Virus particles carrying a mutation in the triplet of NC basic residues (P3BE) show delayed cleavage
of p15NC and a defect in core formation despite the eventual appearance of fully processed virion protein.
These results define determinants of the p15NC-RNA interaction that lead to enhanced protease-mediated
cleavage and demonstrate the importance of the triplet of basic residues in formation of the virus core.
The human immunodeficiency virus type 1 (HIV-1) viral
protease (PR) functions during virion assembly and matura-
tion in the cleavage of the Gag and Gag-Pro-Pol precursors
(47, 58). Without PR activity, virions are released but are not
infectious and retain an immature, spherical morphology (2,
36). Upon cleavage of the precursors, the virion undergoes
maturation with the formation of an electron-dense core, and
particle becomes infectious (19, 30, 32, 56, 58). Little is known
about the process of virion morphogenesis, but it is likely to be
a controlled event given the complexity of virion structure and
its importance in producing an infectious particle.
It has been recognized for some time that the Gag process-
ing sites are cleaved in an ordered manner by PR in the virion
and in vitro (17, 23, 43, 49, 64). Initial cleavage of Gag occurs
at the amino terminus of the NC domain, producing a 15-kDa
intermediate, p15NC (17, 43, 67), consisting of nucleocapsid-
p1-p6 and a 39-kDa intermediate consisting of matrix-cap-
sid-p2 (23, 43, 49). Later in the processing cascade, these
intermediates are further cleaved to yield the mature products
(24, 43, 49, 64). Thus, during virion morphogenesis, there ap-
pear at least four different forms of nucleocapsid (NC): as Gag,
as p15NC, as NC-p1, and as mature NC. The exact role of each
NC form is not known, but the presence of functional differ-
ences between them suggests that each has a particular role
during virion morphogenesis.
Studies of Gag processing in infected cells and in vitro have
provided some indication that the timing of Gag cleavages is
regulated and important for proper virion morphogenesis. Im-
mature HIV-1 particles formed in the presence of PR inhibi-
tors are unable to obtain maturity and infectivity upon removal
of inhibitor (28, 36, 52). Mutation at the CA-p2 region pro-
duces particles with lowered infectivity despite the presence of
the proper final products (33, 49). In similar studies, mutagenic
alteration of the rate at which the matrix-capsid junction is
cleaved results in particles with lowered infectivity (26a). In
addition, RNA enhances cleavage of the p15NC intermediate
in vitro (60), suggesting that external factors have the potential
to influence Gag processing.
Mature NC is composed of 55 amino acids and contains two
zinc fingers of a characteristic C-C-H-C motif separated by a
seven-residue linker (22, 24, 45). Basic residues are frequent in
the areas flanking both fingers and in the linker domain. NC
carries out a number of essential functions, including RNA
dimerization (18, 68) and primer tRNA positioning (4, 42); NC
functions have been recently reviewed (12). NC also modulates
reverse transcriptase (RT) activity through formation of a tri-
partite complex with the primer tRNA (4, 42, 68) and interacts
with the Vpr protein (37). NC as a component of Gag func-
tions in the selection of the specific RNA to be encapsidated
through interaction with the PSI packaging site of the viral
RNA (6, 71). Binding of mature NC, p15NC, or Gag Pr55 to
viral and synthetic RNAs and DNAs has been demonstrated in
a number of in vitro studies (5, 10, 11, 13, 27, 31, 38, 39, 59, 61,
62, 70). Differences in assay conditions preclude direct com-
parisons of such studies, but in general NC-containing proteins
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bind with a Kd in the nanomolar range under conditions of low
salt concentration and in the presence of zinc (10, 11, 31, 59,
62, 70). The binding site size or footprint appears to be smaller
for mature NC than for its larger precursors (14, 31, 38, 39, 70),
and multiple stem-loop structures within the PSI region of the
viral RNA are crucial for this binding (10, 41, 57).
Mutagenic studies of NC peptides and precursors have iden-
tified areas necessary for function. Initial studies recognized
the zinc fingers (1, 7, 11, 15, 20, 21) and basic residues flanking
the first zinc finger (13, 18, 25, 48, 50, 59, 62) as necessary for
viral RNA encapsidation. Others used chimeras from multiple
retroviruses to establish a role for the zinc finger regions of NC
in the selection of the proper RNA for encapsidation (6, 71).
The two zinc fingers appear to have separate and essential
roles in the interaction with viral RNA (7, 20), and the spatial
distance between the fingers is critical (15, 45, 46, 48). An
understanding of the necessity of intact zinc fingers for pro-
duction of infectious virions has led to the recent identification
of a class of zinc finger modification agents designated 2,29-
dithiobisbenzamides which show anti-HIV activity (54, 66).
Mutations of NC have diverse effects on virion morphogen-
esis. Zinc finger mutants have been described as being similar
to the wild type (7, 20, 22) or largely immature (1); differences
in the infectious clones and cell types used may account for
these opposing findings. Where examined, mutagenesis of the
linker between the fingers resulted in aberrant morphogenesis,
in some cases resulting in immature particles (48, 50). Taken
together, these results suggest an important role for NC in
RNA encapsidation and assembly, maturation, and infectivity
of particles.
We previously reported initial results that suggested that
viral protease-mediated cleavage of the p15NC intermediate
was RNA dependent (60). In this study, we investigated the
nature of the interaction between p15NC and RNA in a model
system. We explored the minimal size and structural require-
ments for enhancement of p15 cleavage upon interaction with
nucleic acids. We also investigated by mutagenesis the individ-
ual contribution of a triplet basic of residues located between
the zinc fingers of p15NC. Finally, we determined the role of
this triplet of residues on viral p15NC cleavage, global proteo-
lytic processing, viral RNA content, infectivity, and morpho-
genesis. These results characterize the determinants that influ-
ence p15NC-RNA interaction and demonstrate the importance
of the basic residues at NC positions 32 to 34 in timely cleavage
of p15NC and in core formation during virion morphogenesis.
MATERIALS AND METHODS
Preparation of RNA. RNA corresponding to the coding sequence of p15NC
(nucleotides 1132 to 1534 of the BH10 isolate [44]) was synthesized by in vitro
transcription from plasmid pDAB15 as previously described (60). To prepare
35S-labeled RNA, 0.63 mM [a-35S]UTP (1,000 to 1,500 Ci/mmol) or [a-35S]ATP
(1,100 Ci/mmol) was included in the transcription reaction. Labeled RNA was
recovered from in vitro transcription reactions by extraction with Pro-Cipitate
(Affinity Technology, Inc.) or phenol-chloroform followed by ethanol precipita-
tion. The specific activity of RNA prepared in this way was typically 20 to 30
mCi/nmol. Synthetic RNA oligonucleotides were purchased from the Biochem-
istry Department, University of Pennsylvania, or from Oligos Etc., Inc. (Wilson-
ville, Oreg.). Synthetic oligodeoxynucleotides were synthesized by DuPont
Merck Pharmaceutical Co. or purchased from Oligos Etc. To prepare the 35S-
labeled RNA oligonucleotide designated RNA24, or to prepare 35S-labeled
bovine tRNA, purchased oligonucleotides were labeled at the 59 end, using T4
polynucleotide kinase and [g-35S]ATP at 37°C for 30 min, and purified by Seph-
adex G-25 chromatography (40). The specific activity for RNA24 prepared in this
manner was typically 30 mCi/nmol. The specific activity of bovine tRNA prepared
in this manner was typically 4 mCi/nmol.
Expression and purification of recombinant p15NC. The coding sequence of
HIV-1 p15NC protein (NdeI-BamHI fragment of the BH10 isolate) or of p15NC
containing desired mutations was derived from the in vitro transcription plasmids
previously described (60). Recombinant p15 was expressed by a T7 expression
system in vector pET3A (Novagen) in Escherichia coli BL21(DE3) cells (55).
Three hours postinduction, cells were harvested by centrifugation, broken in a
French press in 50 mM morpholineethanesulfonic acid (MES)–4 M urea (pH
6.5), and clarified by centrifugation. The soluble fraction was enriched for p15NC
protein by using batch chromatography with S-Superose resin (Pharmacia) in 50
mM MES–4 M urea (pH 6.5) and eluting the resin stepwise at 0.25, 0.5, and 1 M
NaCl in the same buffer. The bulk of p15NC was recovered in the 0.5 M NaCl
elution, and this material was dialyzed against 50 mM MES–4 M urea (pH 7.0)
and applied to a Mono S column (Pharmacia). Proteins were eluted with a linear
gradient of 0 to 1 M NaCl in 20 min (HR 5/5 column) or 50 min (HR 10/10
column). Recombinant p15NC eluted at 0.5 to 0.7 M NaCl. Fractions were
pooled, and material from several columns was combined, concentrated, and
applied to a Zorbax Protein Plus reverse-phase high-pressure liquid chromatog-
raphy column in 0.1% trifluoroacetic acid. Proteins were eluted with a gradient
of 0 to 63% CH3CN in 40 min at a flow rate of 2.5 ml/min. The p15NC protein
eluted at 42% CH3CN as assessed by sodium dodecyl sulfate (SDS)-polyacryl-
amide gel electrophoresis (PAGE). The pooled fractions were lyophilized, and
the dried residue was brought up in phosphate-buffered saline (PBS; pH 6.5)
containing 10% (vol/vol) glycerol. The presence of bound zinc in the preparation
was not determined, but the effect of adding or removing zinc on subsequent
processing was later assessed in vitro. The amino-terminal amino acid sequence
of Met-Gln-Arg-Gly-Asn corresponding to native p15NC was confirmed by au-
tomated sequencing (Beckman Instruments). Thus, recombinant p15NC protein
includes only authentic sequences starting from the initiator methionine residue
that is the amino terminus of viral p15NC (44).
Mutagenesis of p15 coding sequences. For generation of p15NC containing
mutations, mutagenesis of both the p15NC transcription-translation vector and
E. coli expression vector was performed as described previously (60). Mutations
were p15NC with first zinc finger cysteine residues 15 and 18 mutated to tyrosine
(CCYY-1); p15NC with second zinc finger cysteine residues 36 and 39 mutated
to tyrosine (CCYY-2); and p15NC with the intra-array basic residues 32Arg-Lys-
Lys34 mutated to glutamic acids (3BE), glutamines (3BQ), or leucines (3BL).
Single-codon substitution mutations in p15 were arginine 32 mutated to glutamic
acid (R32E); lysine 33 mutated to glutamic acid (K33E), and lysine 34 mutated
to glutamic acid (K34E). For generation of p15NC mutations in virus, a subclone
of the HIV-1 HXB2 isolate containing the p15NC coding domain was mutated
by using a commercially available kit. Mutations were p15NC with second zinc
finger cysteine residues 36 and 39 mutated to serine (CS2) and p15NC with the
intrafingers basic residues 32Arg-Lys-Lys34 mutated to glutamic acids (P3BE).
Cleavage of p15NC by HIV-1 protease. Cleavage of p15NC generated by in
vitro transcription-translation reactions was conducted as previously described
(60). Cleavage of purified recombinant p15NC by the HIV-1 protease was car-
ried out in 20 mM sodium phosphate buffer (pH 6.5)–150 mM NaCl (PBS), using
2 to 5 mg of p15NC protein and 0.055 mg of HIV protease (9) in a total volume
of 15 ml. Reactions were carried out in the presence or absence of RNA or DNA
oligonucleotides as indicated in the figure legends. After incubation at 30°C for
60 min, reactions were terminated by addition of an equal volume of SDS-PAGE
sample buffer (34) and boiling for 2 min. Samples from protease digestion of
translation products or recombinant p15NC protein were analyzed on SDS–4 to
20% polyacrylamide gels (Novex) and visualized by Coomassie blue staining.
Recombinant p15NC migrates at an apparent molecular mass of about 17 kDa
as previously noted (17, 49, 60).
Filter binding assay for RNA-p15NC interactions. Filter binding assays were
modified from Draper et al. (16) and similar to assays described previously for
NC-RNA interactions (10, 11, 59, 62, 70). Because of the dependence of filter
retention of complexes on salt concentration, reaction volume, incubation time,
temperature, and filter handling (16), the assay procedure described below was
strictly adhered to. Under these conditions, 50 to 70% of input counts were
reproducibly retained with saturating protein concentrations, well within the
range of retentions described for idealized systems (16). The binding reactions
contained a constant concentration of 35S-labeled HIV-1 RNA (0.5 nM) and
increasing concentrations of p15NC protein (0.1 to 18 nM) in a final volume of
200 ml of PBS. After 60 min of incubation at room temperature, 190 ml of the
reaction was filtered through prewetted HAWP nitrocellulose filters (Waters-
Millipore) under vacuum, washed once with 500 ml of PBS, air dried, and
counted in 10 ml of scintillation cocktail. The filtration and washing steps were
timed (total of 45 s) to ensure consistency of retention percentage. Background
or nonspecific retention of labeled RNA to the filters was determined in parallel
reactions lacking the p15NC protein. The equilibrium dissociation constant, Kd,




$Kd 1 Pt 1 Rt 2 Î~Kd 1 Pt 1 Rt!2 2 4PtRt%
where PRm is the maximum retention of the protein-RNA complex at saturating
protein concentration, Pt and Rt are the total p15NC and RNA concentrations
present in the reaction, and Kd is the dissociation constant for the binding of
RNA by p15NC protein. For competition experiments, unlabeled oligonucleo-
tides, oligodeoxynucleotides, or RNA was diluted in PBS immediately before use
and added to reactions prior to addition of labeled RNA.
Construction of HIV-1 infectious clones, cell transfection, and viral charac-
terization. Subclones of HIV-1 isolate HXB2 containing either the second zinc
finger (CS2) or inter-zinc finger basic amino acid (P3BE) p15NC mutation were
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used to regenerate full-length HXB2 viral clones (51). Purified DNA was isolated
(Qiagen), and the presence of the desired mutations was confirmed by DNA
sequencing. For pulse-chase experiments, HeLa cells (8) were transfected in
six-well plates. At 48 h posttransfection, cells were starved in RPMI medium
minus cysteine for 3 h, followed by a pulse for 45 min in 1 ml of medium lacking
cysteine supplemented with 300 mCi of [35S]cysteine (1,000 Ci/mmol). Cells were
washed twice with medium and chased with 1 ml of complete medium for chase
periods of 1 to 5 h. At times indicated in the figure legends, medium (containing
released virus) was removed, clarified by centrifugation, and mixed with radio-
immunoprecipitation assay buffer (29). The remaining cells were washed and
then lysed in radioimmunoprecipitation assay buffer. Immunoprecipitation of
labeled virion proteins was performed with rabbit polyclonal serum raised to
recombinant p15NC or with HIV-1-infected patient serum as described previ-
ously (29).
For electron microscopy (EM), HeLa cells in 100-mm-diameter plates were
transfected with 20 mg of DNA of the purified infectious clone HXB2 or a clone
containing the P3BE or CS2 mutation as described previously (8). At 48 h
posttransfection, cells were scraped and fixed overnight in 2% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.4). After washing, the cells were postfixed in 2%
osmium tetroxide in 0.1 M cacodylate buffer for 45 min, dehydrated with ethanol,
and embedded in araldite 502/EMbed 812 as instructed by the manufacturer
(Electron Microscopy Sciences). Thin sections were cut and stained with uranyl
acetate and lead citrate prior to examination in a Philips EM400 electron mi-
croscope at a setting of 60 kV.
RESULTS
p15NC-RNA interaction and enhanced proteolytic cleavage
in vitro. Our previous studies with in vitro translation products
corresponding to p15NC and the ;400-nucleotide RNA en-
coding it allowed a sensitive means to measure the RNA-
enhanced processing of p15NC by the viral protease (60). We
found that within this system, the 400-bp p15 transcript was
functionally equal to the full-length Gag transcript in its ability
to enhance protease-mediated cleavage of p15NC. The com-
plex nature of the rabbit reticulocyte expression system, how-
ever, precluded detailed investigation of the mechanism of
RNA-enhanced cleavage. We thus prepared purified p15NC
protein to define the nature of interactions between p15NC
and RNA, which results in increased susceptibility to the HIV
protease. Figure 1 shows the cleavage of purified p15NC (es-
timated purity .95% by densitometry) in the reconstituted
system containing p15NC, purified HIV protease, and p15NC
RNA and also shows the lack of processing when any of the
components is omitted. These results confirm our previous
observation of enhanced cleavage of p15NC in the presence of
RNA (60) and show that in our reconstituted system, the p15
RNA alone is sufficient to act as a positive modulator of pro-
tease-mediated cleavage of p15.
We next examined the binding of purified p15NC protein to
its corresponding RNA transcript, using filter binding and gel
shift assays. Figure 2 shows the saturable binding of recombi-
nant p15NC with labeled RNA transcript, using a filter binding
assay under conditions of fixed RNA concentration and mod-
erate salt concentration (0.15 M NaCl). Saturation occurred
when the level of recombinant protein was about 20- to 30-fold
FIG. 1. Enhanced cleavage of purified p15NC by HIV-1 protease in the
presence of RNA. Purified recombinant p15NC (final concentration, 15 mM),
recombinant HIV protease (18 nM), and p15NC RNA (final concentration, 2
mM) were combined as indicated and incubated in PBS (pH 6.5) for 60 min at
30°C prior to electrophoresis on SDS–8 to 16% polyacrylamide gels and Coo-
massie blue staining. In this gel system, the cleavage products, p6 and p7NC,
comigrate near the dye front.
FIG. 2. Binding of p15NC mRNA to p15NC. Filter binding assays contained a constant concentration of 35S-labeled p15NC RNA (0.5 nM) (closed symbols) or
35S-labeled bovine liver tRNA (1.8 nM) (open symbols). The p15NC concentration was varied from 0 to 18 nM. Samples were filtered after a 60-min equilibration period
at 25°C. Where indicated, 20 nM ZnCl2 or 45 mM EDTA was included to evaluate the role of the NC zinc fingers. The data are shown as fractional binding relative
to input counts per minute. Because the tRNA and p15NC RNA are present at different concentrations, there are two relevant comparisons. If the data are considered
as the molar ratio of p15NC to RNA, then the 18 nM p15NC point of the tRNA binding curve should be compared to a position at 5.5 nM p15NC RNA (70%
saturation). If the ratio is based on total nucleotide concentration, then the 18 nM point should be compared to approximately 12 nM p15NC RNA. In both cases, the
binding to p15NC is approaching saturation providing the sensitivity to distinguish between the specific and nonspecific component interactions.
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that of RNA. In contrast, no saturable, concentration-depen-
dent (specific) binding of labeled tRNA was detected under
these binding assay conditions. RNA does not bind directly to
the HIV protease dimer as measured in filter binding assays. In
the reverse titration, that of fixed p15NC protein, and variable
amounts of labeled RNA, saturation also occurred at a ratio of
protein to RNA species of approximately 30:1 (data not
shown). In gel shift experiments, addition of 0.4 to 7 equiva-
lents of recombinant p15NC protein caused the migration of
RNA to be increasingly retarded in an agarose gel (data not
shown). Formation of the p15NC-RNA complex was not af-
fected by addition of 20 nM ZnCl2 (a fivefold excess relative to
Gag p15NC concentration) or 45 mM EDTA (Fig. 2), suggest-
ing that binding did not involve the Cys-His zinc-binding do-
mains or that the function of the zinc-binding domains was not
affected under these conditions. This result contrasts with the
well-documented role that these domains play in binding to
PSI site regions of HIV RNA (10, 11, 41, 57, 70). The Kd value
estimated from the protein concentration required for half-
maximal binding under these conditions was 1.5 nM. This Kd
estimate, though not rigorously defined, allowed the relative
affinities of various oligonucleotide competitors to be subse-
quently compared.
Basic amino acids located between the zinc fingers are re-
quired for RNA binding and enhanced protease-mediated
cleavage in vitro. The p15NC protein of HIV contains two
conserved zinc-binding, Cys-His finger motifs within the NC
domain that are separated by a flexible linker of seven resi-
dues. The linker contains a triplet of basic amino acids at
positions 32 to 34 (44). Using p15NC produced by in vitro
transcription and translation, we previously showed impaired
cleavage of p15NC when the basic triplet had been mutated to
glutamic acid (3BE) (60). The p15NC mutant 3BE is also
defective for binding RNA under conditions where two muta-
tions that disrupt either Cys-His array (CCYY-1 and CCYY-2)
have no effect on RNA binding or cleavage. Analysis of the
cleavage of recombinant p15NC and p15NC containing the
various mutations confirmed that the zinc finger mutants
bound RNA and displayed cleavage enhancement equal to that
found for the wild type. Purified 3BE p15NC, however, bound
20% as much labeled p15NC RNA and showed reduced cleav-
age by protease (data not shown).
The individual contribution of basic residues 32 to 34 to
RNA-enhanced cleavage was examined by mutagenesis. Figure
3 shows the relative time course for viral protease-mediated
cleavage in the presence of RNA of wild-type and mutant
forms of p15NC in which the basic triplet residues have been
altered. Cleavage was three- to fourfold slower when the three
basic amino acids were changed to glutamic acid, as previously
documented (60), but also when these amino acids were
changed to leucine or glutamine, which are isosteres for lysine
in terms of chain length and hydrogen-bonding capabilities,
respectively. When the three basic amino acids were individu-
ally mutated to glutamic acid, K34E was cleaved 50% more
slowly than wild-type p15NC in the presence of RNA. R32E
and K33E were cleaved at rates similar to wild-type rates.
These results suggested that multiple electrostatic interactions
involving the triplet of basic amino acids play a role in the
protein-nucleic acid interaction that confers protease suscep-
tibility with the terminal lysine (K34) as the key component.
Identification of viral RNA-derived sequences that confer
enhanced protease susceptibility to p15NC. We wished to de-
fine a minimum RNA sequence sufficient to confer enhanced
protease-mediated cleavage by annealing to specific regions of
the p15 RNA. We took two different approaches to determin-
ing the RNA requirement. First, we prepared a library of
contiguous 21-mer oligodeoxynucleotides complementary to
p15NC RNA in an attempt to block enhancement of p15NC
cleavage through heteroduplex formation and assessed the re-
sult in the reconstituted system containing recombinant pro-
tein and added p15NC RNA. Despite several attempts using a
variety of ratios of synthetic oligodeoxynucleotide to p15NC
RNA and different annealing conditions, no inhibition of pro-
tease-mediated cleavage of p15NC was observed (data not
shown). However, we noticed that one synthetic oligode-
oxynucleotide, designated N-5, actually enhanced the cleavage
of in vitro-translated p15NC when added to this system. This
result was surprising, as previous experiments had suggested
that small oligodeoxynucleotides were poor modulators of
p15NC cleavage (60).
We then examined directly the ability of this set of oligode-
oxynucleotides to potentiate the cleavage of purified p15NC by
the HIV protease in the reconstituted system. As shown in Fig.
4 (lane 5), only oligodeoxynucleotide N-5 showed ability to
confer susceptibility to the viral protease comparable to the
result for the control cleavage reaction (lane A). Three other
oligodeoxynucleotides, N-12, N-14, and N-16 (Fig. 4, lanes 12,
FIG. 3. Cleavage of wild-type and mutant forms of p15NC in vitro. Mutant
and wild-type p15NC species were generated via in vitro transcription-translation
as described in Materials and Methods. All samples were digested with purified
HIV protease at 30°C; aliquots were removed at the times indicated and ana-
lyzed by SDS-PAGE. An Ambis Radioanalytic Scanner was used for quantita-
tion. Curves represent the averages from two to five time course experiments.
The courses of proteolysis with wild-type p15NC, 3B mutants, and single mutants
at positions 32, 33, and 34 are indicated.
FIG. 4. Oligodeoxynucleotides of particular sequence enhance cleavage of
purified p15NC in vitro by protease. All reaction mixtures contained purified
p15NC (final concentration, 15 mM), HIV protease (18 nM), and 2 mM synthetic
21-mer oligonucleotide in PBS. Reaction mixtures were incubated at 30°C for 60
min, and products were visualized via SDS-PAGE and Coomassie blue staining.
Lane A, 2 mM p15NC RNA; lanes 1 to 18, contiguous 21-mer oligodeoxynucle-
otides.
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14, and 16), also conferred susceptibility to protease cleavage
but to a much lower degree. A contiguous set of 21-base
oligodeoxynucleotides prepared in the sense orientation (des-
ignated S-1 to S-18) failed to enhance cleavage significantly,
although there was a discernible loss of substrate in the reac-
tion corresponding to oligodeoxynucleotide S-5 (data not
shown). S-5 and its complement N-5 correspond to the region
that encodes NC residues 29 to 34 between the Cys-His fingers
and contain internal complementary sequences (see Fig. 5A
for their sequences).
In the second approach, we mapped the area of p15NC
RNA responsible for enhanced cleavage of p15NC. We used
two restriction sites within the p15NC portion of the in vitro
transcription-translation plasmid, pDAB15, to generate trun-
cated RNA species (Fig. 5A). Transcription of plasmid linear-
ized with BglII produces a truncated transcript corresponding
to nucleotides 1 to 200 of the p15NC sequence, a region that
encodes NC through both zinc fingers. Transcription of the
plasmid linearized with AvrII produces a transcript of ;100
nucleotides, representing coding sequence through the region
corresponding to the first zinc finger of NC and ending just
short of the region to which oligonucleotide N-5 maps. When
we compared BglII and AvrII RNAs to the full-length p15
transcript with respect to the ability to confer enhanced sus-
ceptibility to viral protease cleavage, we observed that BglII
RNA but not AvrII RNA enhanced cleavage of p15NC by the
viral protease (Fig. 5B). The shorter AvrII RNA was quite
inefficient compared to the longer RNA species even with
eightfold more RNA present in the reaction (data not shown).
This result suggested either than an RNA species of ;100
nucleotides was not sufficient to support HIV protease-medi-
ated cleavage or that sequences and/or secondary structures
found in nucleotides 100 to 200 were necessary for the RNA-
enhanced cleavage of p15. Considering the findings from the
oligonucleotide mapping experiments, we further explored the
latter possibility.
We mapped the RNA sequences required for RNA-en-
hanced cleavage of p15NC by determining the ability of a
synthetic RNA species corresponding to the first 48 bases of
the region defined by AvrII and BglII (designated RNA48) and
correspondingly smaller fragments (RNA24, RNA18, and
RNA15) to enhance HIV PR-mediated cleavage of recombi-
nant p15NC (Fig. 5B). We observed that RNA48 and RNA24
were comparable to full-length p15NC RNA (on a molar basis)
in enhancing protease-mediated cleavage of p15NC, whereas
RNA18 and RNA15 were less efficient, in that visible substrate
remained after a 30-min digestion period. An RNA species of
9 nucleotides, corresponding to the middle portion of RNA15,
did not measurably enhance cleavage of p15NC (data not
shown). Use of the GCG program MFOLD (65, 72) which
considers both AU, GC, and GU potential base pairs, pre-
dicted a thermodynamically favorable folding pattern of a 5-bp
stem-loop for both RNA24 and oligodeoxynucleotide N-5.
We prepared 59-end 35S-labeled RNA24, in order to directly
compare its binding to p15NC to that of full-length p15NC
RNA. The apparent Kd for
35S-labeled RNA24 binding by
purified p15NC protein was about threefold higher than for
binding of full-length p15NC RNA (Kd 5 5.2 nM). A reduced
interaction was further inferred by the lessened ability of un-
labeled RNA24 to compete with labeled p15 RNA compared
to unlabeled p15 RNA (not shown). We also investigated the
ability of synthetic oligodeoxynucleotide analogs of N-5 to
compete with labeled p15NC RNA for p15NC binding. Oli-
godeoxynucleotide N-5 was able to compete with labeled
p15NC RNA for binding, but S-5 or two oligodeoxynucleotides
identical in base composition to N-5 and S-5 but with random
sequence were not (Fig. 6). Oligodeoxynucleotide N-5GT, con-
taining a G-to-T substitution to disrupt the stem-loop, was also
less effective over the concentration range examined. Taken
together, these data suggest that binding of p15NC to highly
localized regions of RNA secondary structure confers the in-
crease in HIV protease susceptibility. Structural studies to
elucidate the precise location of the interaction(s) suggested
from the binding and processing studies described here are in
progress.
Mutagenesis of NC basic residues 32 to 34 affects HIV-1
viral morphogenesis. Our results indicated the necessity of the
basic residues located at positions 32 to 34 of the NC domain
in the recognition of nucleic acids and the upregulation of
p15NC in vitro. To evaluate the importance of these residues
to virion assembly, we placed the 3BE mutation (designated
P3BE) in an infectious clone of HIV-1 and transfected the
clone into HeLa cells to produce virus. As a control, we con-
structed a second viral clone containing the CS2 mutation
(substitution of second zinc fingers cysteine residues 36 and 39
with serines). The CS2 mutation is actually located closer to
the affected protease cleavage sites in the p15 precursor than
the P3BE mutation. The virus morphology of the CS2 muta-
tion has been previously characterized in the pNL4-3 back-
ground by Gorelick et al. (22). Two days posttransfection, the
effect of the mutations was determined. Western blot analysis
showed no defect in global proteolytic processing, as similar
extents of processing of Gag to matrix (p17), p24-capsid, and
p15NC were seen (not shown).
Pulse-chase analysis of Gag processing, however, indicated
an altered rate of processing of p15NC with the P3BE muta-
FIG. 5. Truncated RNAs support HIV protease-mediated cleavage of
p15NC. (A) Diagram showing locations of AvrII and BglII restriction endonu-
clease sites within the p15NC region and sequence of synthetic RNA species
used to probe RNA requirement for HIV protease-mediated cleavage of p15NC
protein. Below are the sequences of DNA and RNA oligonucleotides tested for
the ability to enhance cleavage of p15 in vitro. The complementary bases with the
potential to form a stem-loop structure are underlined. (B) Protease digestion of
purified p15NC protein. Purified HIV protease was added to p15NC in PBS (pH
6.5) in the presence of the following: lane 1, no added RNA; lane 2, 60 pmol of
full-length p15NC RNA; lane 3, 60 pmol of BglII runoff transcript; lane 4, 60
pmol of AvrII runoff transcript; lane 5, 60 pmol of RNA48; lane 6, 60 pmol of
RNA24; lane 7, 60 pmol of RNA18; lane 8, 60 pmol of RNA15.
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tion compared to wild-type p15NC. P3BE p15NC was cleaved
more slowly than the wild type in cells and in released virions,
and precursor was evident even after a 5-h chase (Fig. 7). The
CS2 mutation resulted in a p15NC intermediate that was ac-
tually less stable than the wild type. In contrast to the differ-
ential phenotypes of the P3BE and CS2 mutations on the rate
of cleavage of p15NC, both mutations resulted in a small delay
in cleavage at the CA-p2 site (not shown). We previously noted
that the rate of cleavage of the CA-p2 site is downregulated by
downstream conformational changes induced through the p2
domain (49, 64). Neither mutation had a significant effect on
overall protease activation, as the half-life of the full-length
Gag precursor and the generation of the CA-p2 intermediate
were similar to those for the wild type during the chase period.
Furthermore, the mutations did not affect packaging of Gag-
Pol products into virions. Amounts of processed RT were
similar to wild-type amounts as determined by Western blot
analysis (data not shown). While the mutations had little effect
on particle release as judged by medium-associated RT activity
or p24 levels, the infectivity of the released virions was severely
impaired. P3BE and CS2 virions were reduced at least 100-fold
in infectivity as determined by MAGI cell assay (29), and these
particles were unable to establish a productive infection of
CEM cells. These infectivity results and the lack of a gross
processing defect are similar to those reported by others for
zinc finger and inter-zinc finger array mutants (1, 15, 20–22,
48). The RNA level in released virions from the 48-h CS2
transfection was 37% of that for the wild type (adjusting for the
small difference in p24 measured), whereas the RNA level in
P3BE virions was less than 12% of that for the wild type, as
measured by a sensitive RNA hybridization-based assay (3).
Gorelick et al. previously reported that in the CS2 mutant,
virion RNA levels were 20% of the wild-type level and that the
virions had a wild-type morphology (22).
When released virions were examined by thin-section EM, a
unique morphology was observed for the P3BE virus (Fig. 8).
Upon cursory examination, the P3BE virions were somewhat
similar in morphology to immature or protease-deficient viri-
ons in lacking a condensed core (28, 52). However, P3BE
virions are clearly different from immature virions in that the
center contains diffuse material. In addition, the electron-
dense material juxtaposed to the membrane lacks the typical
banding pattern observed in immature wild-type HXB2 viri-
ons. Thus, the P3BE virions are defective for core formation
despite the eventual cleavage of Gag and Gag-Pro-Pol to the
final products. No P3BE virions were observed with the wild-
type morphology of a condensed core in any field examined.
Wild-type and CS2 fields contained both immature and fully
mature virions, consistent with earlier observations (1, 20, 22).
DISCUSSION
Previously we reported that cleavage of the p15NC process-
ing intermediate was upregulated by the presence of Gag
mRNA during the processing of the full-length Gag in vitro
(60). In this report, we refined the components of the in vitro
system in order to obtain a more detailed examination of the
determinants required for upregulation of p15NC cleavage
upon interaction with viral RNA. With purified components,
we determined that p15-encoding RNA is the only additional
component necessary for enhanced cleavage of the p15NC in
vitro. Through a systematic approach, we have defined several
determinants on both the RNA and p15NC necessary for max-
imal upregulation of p15NC cleavage in vitro. Additionally, we
FIG. 6. Ability of synthetic oligodeoxynucleotides to displace 35S-p15NC
RNA in the filter binding assay. Reaction mixtures contained 4 nM Gag p15NC,
0.5 nM 35S-labeled RNA, and the indicated concentration of unlabeled oligode-
oxynucleotide in PBS. Closed circles, oligodeoxynucleotide N-5 (GCCCTTTTT
CCTAGGGGCCCT); closed triangles, oligodeoxynucleotide S-5 (AGGGCCC
CTAGGAAAAAGGGC); open squares, oligodeoxynucleotide N-R (GCTCGT
TTATTCCCTGGGCCC); open circles, oligodeoxynucleotide S-R (GCAGCAA
ATAAGGGACCCGGG); closed squares, oligodeoxynucleotide N-5GT (GCC
CTTTTTCCTAGGTGCCCT).
FIG. 7. Pulse-chase analysis of p15NC processing in infected cells and re-
leased virions. HeLa cells transfected with the wild-type HXB2 full-length viral
clone or a clone containing mutations in the NC coding domain were prepared
as described in Materials and Methods. Following [35S]cysteine pulse-labeling
and chase, released virions and cell extracts were immunoprecipitated with
antibodies to purified p15NC and separated by SDS-PAGE. Wild-type HXB2
isolate (WT) and the CS2 and P3BE mutants were compared. The positions of
molecular mass markers and of p15NC and mature NC are shown.
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FIG. 8. Electron micrographs of virions containing the P3BE mutation. HeLa cells were transfected with the P3BE-HXB2 infectious clone and prepared for EM
as described in Materials and Methods. The picture of released P3BE mutant virions was taken at a magnification of 18,000. The inset of a single P3BE particle at higher
magnification shows in detail the unique morphology of the mutant. No virions of wild-type morphology were observed.
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investigated mutations in the residues in p15NC necessary for
RNA enhanced cleavage in vitro for their effects on the assem-
bly and morphogenesis of virions.
The p15NC-p15NC RNA interactions that we observed in
the enhanced cleavage by the viral protease involve a specific
region of this portion of the viral RNA and NC-precursor
protein. Using a combination of runoff transcripts and syn-
thetic oligonucleotides, we found a minimum-sized oligonucle-
otide fragment capable of interacting with the recombinant
p15NC and positively modulating cleavage by HIV protease.
An RNA species of 24 nucleotides, RNA24, contained within
the p15NC RNA sequence was fully competent for binding to
p15NC and imparting enhanced susceptibility to HIV pro-
tease-mediated cleavage (Fig. 5B). The binding interaction(s)
leading to protease-mediated cleavage was not limited to
RNA. Oligodeoxynucleotide N-5, predicted to form a stem
loop (DG 5 26.9 kcal/mol), was able to function, albeit less
efficiently than p15NC RNA (N-5 bound with 5- to 10-fold
lower affinity), in the enhancement of p15NC cleavage. The
complement of this sequence (S-5), which forms a less stable
stem-loop DG 5 24.9 kcal/mol), and random or stem-loop-
disrupted oligodeoxynucleotides of identical composition
failed to interact with p15NC as detected by binding and cleav-
age assays. This result strongly suggests that a particular sec-
ondary structure is an important determinant of the interaction
that permits enhanced cleavage of p15NC by the viral protease.
The possible mechanisms of cleavage upregulation include
polynucleotide-mediated conformational effects to expose bur-
ied cleavage sites, stabilization of substrate-enzyme binding,
and transition state stabilization. Although beyond the scope
of this study, such possibilities may be testable by using more
sophisticated binding assay methodologies.
The requirement for stem-loop-forming ability explains, in
part, the apparent discrepancy with our earlier observation
that oligodeoxynucleotides showed no enhancement of p15NC
cleavage in the in vitro transcription system (60). The oligode-
oxynucleotides tested previously contained no significant in-
verted repeats. However, full-length single-stranded p15NC
DNA was also ineffective in conferring protease susceptibility
(60). Perhaps other secondary structures were favored with this
DNA species that were unfavorable for p15NC binding. The
AvrII transcript, which was also inefficient in enhancing p15NC
cleavage (Fig. 5) and predicted to have a complicated second-
ary structure by MFOLD (65, 72), supports the idea that par-
ticular secondary structural elements are involved in the RNA-
p15NC-protease interaction. Sequence requirements may add
further complexity to the stem-loop requirement; preliminary
studies suggest that partial cleavage enhancement (at the p1-p6
junction) results with stable stem-loops regardless of sequence,
whereas completion of the p7NC-p1 processing step is se-
quence dependent (48a).
The RNA and DNA oligonucleotides in this model system
represent only a fraction of the potential secondary structure
found in virion RNA. We found by MFOLD at least four other
regions of the viral genome, corresponding to nucleotides 2483
to 2498 (within pol), 6929 to 6951 and 7103 to 7117 (within
env), and 4666 to 4680 (within a splice junction), that have
small stem-loop-forming regions similar to that defined by
RNA24. Wu et al. recently described the interaction of a stem-
loop region of murine leukemia virus RNA located near the
polypurine tract with HIV-1 NC which resulted in an improved
efficiency in DNA synthesis (69). These authors suggested
there might be a similar role for NC and stem-loop regions
within HIV-1. Further studies to elucidate whether the homol-
ogous regions that our search has identified bind to p15NC are
in progress.
Decreased cleavage of the P3BE p15NC mutant in cells and
virus particles (Fig. 7) suggests that the interaction between
p15NC and RNA is an important feature of virion morpho-
genesis, although we have not determined the effect of this
mutation on p15NC folding. If appropriately timed cleavage of
the p15NC in virions does require RNA, then our experiments
raise several issues. First, if the cleavage is promoted by bind-
ing to a small number of specific features of RNA secondary
structure, as suggested by the productive interaction with a
small region of p15NC RNA, then each RNA structure must
bind many p15NC molecules sequentially, with the cleaved,
mature p7NC dissociating to bind elsewhere on the RNA. The
relative dissociation constants of 1.5 nM for p15NC and ;20
nM for p7NC (59) and the determination of high- and low-
affinity binding states for p7NC that vary with p7NC/RNA ratio
(14, 31, 70) are consistent with such sequential binding inter-
actions. Previously, a model for RNA-dependent maturation
of Rauscher leukemia virus which involved multiple, sequential
binding interactions was proposed based on inferences derived
from actinomycin D effects (26). Alternatively, since we have
tested only a small proportion of the genome, we do not know
the density of RNA binding sites that could contribute to
accelerated p15NC cleavage in vivo. Finally, the generation of
some mature p7NC may be sufficient to allow cleavage of the
remaining p15NC intermediates through complex protein-pro-
tein interactions. Such a model would predict rate enhance-
ments late in the course of p15NC cleavage. The time-depen-
dent decrease in rate that we typically observe in vitro, which
we have reasoned reflects the dissociation of protease dimers
at the low concentrations used, may have obscured such effects.
These models suggest several experiments, including a need to
know the fate of p15NC in virions made without RNA.
The structure of the NC domain within the p15NC precursor
intermediate is not known. Several lines of evidence suggest
that the domain within the p15NC precursor has a conforma-
tion different from that of fully processed p7NC. Tanchou et al.
(63) noted differences in the binding of conformationally sen-
sitive monoclonal antibodies to mature NC versus p15NC. We
have also identified apparent conformation-dependent mono-
clonal antibodies within a panel raised to p15NC (63a). Others
have suggested a difference in the specific recognition of viral
RNA and in the size of the binding site or footprint on RNA
(14, 31, 38, 70). Thus, the different forms of NC present during
the maturation phase of the viral life cycle may have distinct
functions during virion morphogenesis. Controlling the ap-
pearance of the various forms through regulation of p15NC
cleavage may be an important aspect of viral maturation.
In terms of the specific regions of the p15NC involved, the
triplet of basic amino acids located between the zinc fingers are
crucial as determined for both RNA binding and protease
cleavage upregulation (Fig. 3). The residues of the fingers and
the fingers themselves have been extensively studied via nu-
clear magnetic resonance analysis and mutagenesis of mature
p7NC (12, 13, 35, 38, 45, 46, 48, 50, 61). Nuclear magnetic
resonance structures of HIV-1 NC suggest the area between
the fingers plays a role in the coordination of the zinc fingers.
Pro-31 causes a kink in the linker that brings the fingers in
closer proximity (46). Mutation of Pro-31 to the bulkier leucine
affects both viral assembly and maturation (46, 48). Phe-16,
Trp-37, and Met-46 interact through van der Waals contacts
with the viral RNA (35, 45, 46). The linker region has thus
been described as being independently flexible from the rigid
fingers, with Lys-33 and Lys-34 solvent exposed and available
for interactions (45, 46). Our mutational analysis studies sug-
gest Lys-34 is the most critical residue involved, but additional
interactions involving Arg-32 and Lys-33 are required for full
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enhancement of protease cleavage (Fig. 3). This interpretation
is similar to the conclusions by Poon and Aldovini (50), who
found that multiple mutations had a more significant effect on
NC function. Arg-32 has been strongly linked to PSI site RNA
binding and infectivity (11, 48, 50). In contrast to the impor-
tance of the triplet of basic residues, mutation of the second
zinc finger had little effect on binding and protease-mediated
cleavage in vitro (Fig. 7) or on virion morphology (22) despite
the fact that this region is closer to the scissile bond. Thus, the
specificity that we have determined for p15NC cleavage en-
hancement by RNA overlaps, but is not identical to, that de-
scribed for PSI site binding-mediated effects (5, 10, 11, 13, 25,
27, 31, 38, 39, 59, 61, 62, 70).
An obvious prediction of our proposed role for the intra-
Cys-His basic array is that viruses with mutations in this region
should show specific defects in processing, namely, in p15NC
maturation. Studies that have been carried out with packaging-
defective mutant virus have concluded that protease-mediated
processing is independent of RNA packaging or particle as-
sembly (1, 11, 13–15, 20, 22, 50, 53, 59). In general, the probes
and methods used to assess processing were focused on p24-
containing regions of Gag. We have shown that virions con-
taining the P3BE mutation are delayed selectively in p15NC
cleavage and are defective for core formation despite the even-
tual appearance of the final processed products. Other viral
mutants that disrupt the zinc finger motifs and result in defec-
tive virion RNA packaging have wild-type morphology similar
to that of the CS2 mutant presented here (20, 22). Thus, the
altered morphology that we observed appears not to be due to
a lack of viral RNA per se. Others have reported NC mutations
that result in virion morphology similar to that of the P3BE
mutation, although most of these other mutations appear to
have more of a global effect on protease activity and virion
release (15, 50, 53). Our results with the P3BE mutation dem-
onstrate the importance of the triplet of basic residues in the
core formation and suggest that this mutation is in a separate
phenotypic class.
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